Trial Profile
BrUOG 355: A Pilot Feasibility Study Incorporating Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin
- Indications Cervical cancer
- Focus Therapeutic Use
- 30 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 05 Apr 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 05 Apr 2021 Status changed from recruiting to active, no longer recruiting.